Company profile
OnKure Therapeutics, Inc.
NASDAQ:OKURBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Bocodepsin Besylate | phase1_2 | — | 2 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03931681 | phase1 | completed | 2019-05-08 | 2021-11-27 | OnKure, Inc. | A Study of OKI-179 in Patients With Solid Tumors |
| NCT06239467 | phase1 | active_not_recruiting | 2024-02-26 | 2026-12-31 | OnKure, Inc. | First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer |
| NCT05340621 | phase1_2 | completed | 2022-05-11 | 2025-01-29 | OnKure, Inc. | NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2) |
FDA applications (0)
No records yet.